LIFECORE BIOMEDICAL, INC. Long-Term Debt, Maturity, after Year Five
LIFECORE BIOMEDICAL, INC. (LFCR) had Long-Term Debt, Maturity, after Year Five of $6.59 million as of 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-03-16
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $6.59M.
- 2025-09-30: Long-Term Debt, Maturity, after Year Five $6.59M.
- 2025-05-25: Long-Term Debt, Maturity, after Year Five $7.35M.
- 2025-02-23: Long-Term Debt, Maturity, after Year Five $7.35M.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $6.59M 10-KT · filed 2026-03-16 |
| 2025-09-30 | $6.59M 10-Q · filed 2025-11-06 |
| 2025-05-25 | $7.35M 10-K · filed 2025-08-07 |
| 2025-02-23 | $7.35M 10-Q · filed 2025-04-03 |
| 2024-11-24 | $2.51M 10-Q · filed 2025-01-02 |
| 2024-08-25 | $2.51M 10-Q · filed 2024-10-04 |
| 2024-05-26 | $160.60M 10-K · filed 2024-08-26 |
| 2016-05-29 | $14.19M 10-K · filed 2016-08-01 |
| 2015-05-31 | $10.16M 10-K · filed 2015-07-31 |
| 2014-05-25 | $11.76M 10-K · filed 2014-08-01 |
| 2013-05-26 | $15.36M 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |